Similarly, in metastatic melanoma, patients receiving cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors demonstrated clinical benefit when their tumors exhibited a high TNB [66]. This evidence concerns the gene CTLA4 and metastatic melanoma.